INTRODUCTION
With fewer than two dozen detailed cases reported in the literature, primary diffuse large B-cell lymphoma (DLBCL) of the vulva is a rare entity.
Although non-Hodgkin lymphomas (NHL) such as DLBCL most often arise from lymph nodes, bone marrow, or spleen, up to 24% of NHL can present primarily at extranodal sites such as the gastrointestinal tract and skin. 1 Less common is the occurrence of primary extranodal NHL at sites along the female genital tract. Although disseminated lymphomas frequently involve structures within the female genital tract, only an estimated 1.5% of NHL are primary extranodal tumors of the female genital tract, anatomically reported in the following order of prevalence: ovary (49%), uterus (29%), fallopian tube (11%), vagina (7%), and vulva (4%). 1, 2 Of these sites, DLBCL is the most common subtype of primary NHL identified within the female genital tract in general and in the vulva specifically. 3 We report 2 new cases of primary DLBCL of the vulva with associated literature review.
CASE REPORTS Case 1
A 38-year-old HIV-negative woman from Iraq, gravida 2 para 2, presented with 1-week history of a vulvar ulceration, which yielded positive herpes simplex virus (HSV) 2 direct fluorescent-antibody, treated with valacyclovir. Over the next 8 months, slow enlargement of minimally tender nodular induration at the site prompted biopsy of an approximately 1-to 2-cm tumor.
Histopathology found dense sheets of large lymphoid cells staining positively for CD20, PAX-5, CD-79, Bcl-2, and MUM1, consistent with DLBCL, with features compatible with primary DLBCL, leg type (Fig 1) . 4 No constitutional symptoms or lymphadenopathy were reported.
Positron emission tomography/computed tomography scan and bone marrow biopsy found no evidence of systemic involvement, yielding Ann Arbor stage IE. She underwent definitive localized radiation therapy (total dose of 36 Gy in 18 fractions followed by an electron boost to the vulva of 6 Gy) with remission of her disease, with continued remission 7 years later.
Case 2
A 73-year-old woman of European descent, gravida 2 para 2, presented with a 2-month history of a mass involving the clitoris and right anterior aspect of the labium minus, measuring 4 3 2 3 1.5 cm. Initial biopsy found a dense lymphoid infiltrate composed 
of CD20
1 lymphocytes featuring medium-to largesized centroblastlike cells, co-expressing Bcl-2, CD23, and weak CD10, but not Bcl-6, CD3, CD5, or cyclin D1. Wide excision of the lesion 3 weeks later found large cells in a vaguely nodular pattern (Fig 2) staining positively for CD20, CD10, Bcl-2, Bcl-6, and MIB-1 (60%) but negatively for MUM1 and EpsteinBarr encoding region, interpreted as DLBCL, germinal center B-cell (GCB) type.
Bone marrow biopsy and 18F-fluorodeoxyglucose positron emission tomography-computed tomography scan found no further evidence of malignancy, yielding Ann Arbor Stage IE. No further therapy was administered. No systemic disease has been seen by computed tomography imaging during surveillance up to 65 months from diagnosis.
DISCUSSION
These 2 cases add experience with primary vulvar DLBCL to our limited literature to date, thereby expanding our understanding of this poorly characterized condition. Our cases share the similar clinical presentation of a localized enlarging mass, with the first case notably preceded by herpetic infection. Pathologically, both cases manifested classic DLBCL architecture and cytomorphology; by immunohistochemistry, the first case exhibited a profile more in keeping with classic leg type primary cutaneous DLBCL (MUM-1 positive), whereas the second case qualified as a GCB-type DLBCL (CD10 and Bcl-6 positive). Both cases shared good response to local therapy.
Review of the literature on primary vulvar DLBCL is limited by small numbers and retrospective nature of reports, variably detailed immunohistochemical AWD, Alive with disease; AWOD, alive without disease; CR, complete remission; CT, chemotherapy; DLBCL, diffuse large B-cell lymphoma; DLCL, diffuse large cell lymphoma; DOD, died of disease; DWD, died with disease; PCDLBCL-LT, primary cutaneous diffuse large B-cell lymphoma e leg type; PCDLBCL (NOS), primary cutaneous diffuse large B-cell lymphoma e not otherwise specified; PMH, past medical history; PROVECIP, vinblastine, procarbazine, prednisone; RT, radiation therapy; SO, salpingo-oophorectomy; TAH, total abdominal hysterectomy.
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analysis and application of now obsolete classifications; nevertheless, some clues as to the nature of the condition emerge in the context of known cases. Search of PubMed/Medline English-language literature databases identified 20 additional cases of apparent localized vulvar masses with DLBCL or likely DLBCL diagnosis (stage I/II) ( Table I) . Based on our case review, primary vulvar DLBCL is a condition affecting women with a mean age of 58, a median age of 64, range of 25 to 79, bimodally distributed between 25 and 43 and 61 to 79, with an average length of follow-up of 28 months (Table I) . Based on 20 of 22 cases of vulvar DLBCL that reported clinical presentations, 8 of 20 cases (40%) presented with ulceration, 30% with enlarging mass, and 25% with nontender mass. Pruritus, erythema, and edema have also been described.
When placed in the context of prior reported cases of primary vulvar DLBCL, our cases appear to fit a larger narrative of frequently treatmentresponsive disease with good initial prognosis (Table I) . Generally, management of primary vulvar DLBCL has included excision, radiotherapy, and chemotherapy, each alone and in combination, without clear superiority of any specific therapeutic intervention. Including the current cases, of the 22 patients reviewed in the literature, 2 are reported to have died of disease. One was a 25-year-old HIVpositive woman presenting with an ulcerated large (up to 12 cm) mass with concurrent weight loss. She had stage IE disease that did not respond to low-dose cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (CHOP)-bleomycin and only partially responded to radiotherapy. The patient died 7 months after diagnosis. 12 The other was a 67-year-old woman with stage IIE DLBCL manifesting as a pruritic mass that achieved complete response with chemotherapy and radiation therapy. The disease was followed by recurrence in the spine, and the patient died 2 years after the initial diagnosis. 3 Dissecting the data further, the 25-year-old woman who died of disease represented 1 of 2 patients who experienced only a partial response to therapy, comprising 12.5% of the total cases with reported outcomes (2 of 16). Both of these partialresponse patients were notably younger and African American and had bulky, ulcerated tumors of 10 cm or larger, features which may portend adverse prognosis.
Of note, the vulva, situated at a unique interface between skin and mucosal lymphoid tissue, represents a site of DLBCL presentation whose accurate categorization as primary cutaneous or nodal is uncertain. Our 2 additional patients, reviewed in the context of the available literature, add to the characterization of vulvar DLBCL as a lymphoma affecting a broad age range, with variably nodular presentations, and with a generally good initial response to treatment.
